{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,31]],"date-time":"2026-10-31T11:41:31Z","timestamp":1793446891555,"version":"4.5.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T00:00:00Z","timestamp":1648598400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Eur J Clin Microbiol Infect Dis"],"published-print":{"date-parts":[[2022,5]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Dalbavancin and comparators were susceptibility tested against 8643 Gram-positive bacteria from 74 hospitals located in Europe and the United States by broth microdilution method. The most common organisms were <jats:italic>Staphylococcus aureus<\/jats:italic> (45.2%), <jats:italic>Enterococcus faecalis<\/jats:italic> (12.2%), and <jats:italic>Staphylococcus epidermidis<\/jats:italic> (8.9%), but rank order varied markedly by geographic region. Dalbavancin demonstrated potent activity and broad spectrum, with MIC<jats:sub>90<\/jats:sub> values of 0.03\u00a0mg\/L for <jats:italic>Staphylococcus aureus<\/jats:italic>, \u03b2-haemolytic streptococci, and viridans group streptococci; 0.06\u00a0mg\/L for <jats:italic>Enterococcus faecalis<\/jats:italic> and <jats:italic>Staphylococcus epidermidis<\/jats:italic>; and 0.12\u00a0mg\/L for vancomycin-susceptible <jats:italic>Enterococcus faecium<\/jats:italic>. All organisms, except vancomycin-resistant enterococci and 1 <jats:italic>Staphylococcus haemolyticus<\/jats:italic> isolate, were inhibited at\u2009\u2264\u20090.25\u00a0mg\/L of dalbavancin.<\/jats:p>","DOI":"10.1007\/s10096-022-04437-0","type":"journal-article","created":{"date-parts":[[2022,3,30]],"date-time":"2022-03-30T22:03:29Z","timestamp":1648677809000},"page":"867-873","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Antimicrobial activity of dalbavancin against Gram-positive bacteria isolated from patients hospitalized with bloodstream infection in United States and European medical centers (2018\u20132020)"],"prefix":"10.1007","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7022-6644","authenticated-orcid":false,"given":"Helio S.","family":"Sader","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0126-1782","authenticated-orcid":false,"given":"Mariana","family":"Castanheira","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9769-9019","authenticated-orcid":false,"given":"Michael D.","family":"Huband","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1215-5216","authenticated-orcid":false,"given":"Dee","family":"Shortridge","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2734-3754","authenticated-orcid":false,"given":"Cecilia G.","family":"Carvalhaes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8648-1137","authenticated-orcid":false,"given":"Rodrigo M.","family":"Mendes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,3,30]]},"reference":[{"issue":"2","key":"4437_CR1","doi-asserted-by":"publisher","first-page":"151","DOI":"10.1016\/j.cmi.2019.10.031","volume":"26","author":"WV Kern","year":"2020","unstructured":"Kern WV, Rieg S (2020) Burden of bacterial bloodstream infection-a brief update on epidemiology and significance of multidrug-resistant pathogens. Clin Microbiol Infect 26(2):151\u2013157","journal-title":"Clin Microbiol Infect"},{"issue":"7","key":"4437_CR2","doi-asserted-by":"publisher","first-page":"e00355","DOI":"10.1128\/AAC.00355-19","volume":"63","author":"DJ Diekema","year":"2019","unstructured":"Diekema DJ, Hsueh PR, Mendes RE, Pfaller MA, Rolston KV, Sader HS, Jones RN (2019) The microbiology of bloodstream infection: 20-year trends from the SENTRY Antimicrobial Surveillance Program. Antimicrob Agents Chemother 63(7):e00355","journal-title":"Antimicrob Agents Chemother"},{"issue":"1","key":"4437_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.jinf.2018.03.005","volume":"77","author":"JF McNamara","year":"2018","unstructured":"McNamara JF, Righi E, Wright H, Hartel GF, Harris PNA, Paterson DL (2018) Long-term morbidity and mortality following bloodstream infection: a systematic literature review. J Infect 77(1):1\u20138","journal-title":"J Infect"},{"issue":"10","key":"4437_CR4","doi-asserted-by":"publisher","first-page":"2748","DOI":"10.1093\/jac\/dky235","volume":"73","author":"MA Pfaller","year":"2018","unstructured":"Pfaller MA, Mendes RE, Duncan LR, Flamm RK, Sader HS (2018) Activity of dalbavancin and comparator agents against Gram-positive cocci from clinical infections in the USA and Europe 2015\u201316. J Antimicrob Chemother 73(10):2748\u20132756","journal-title":"J Antimicrob Chemother"},{"issue":"23","key":"4437_CR5","doi-asserted-by":"publisher","first-page":"2169","DOI":"10.1056\/NEJMoa1310480","volume":"370","author":"HW Boucher","year":"2014","unstructured":"Boucher HW, Wilcox M, Talbot GH, Puttagunta S, Das AF, Dunne MW (2014) Once-weekly dalbavancin versus daily conventional therapy for skin infection. N Engl J Med 370(23):2169\u20132179","journal-title":"N Engl J Med"},{"key":"4437_CR6","volume-title":"Package insert","author":"Dalvance\u00ae,","year":"2018","unstructured":"Dalvance\u00ae, (2018) Package insert. Allergan USA Inc, Madison"},{"issue":"3","key":"4437_CR7","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1007\/s40121-015-0077-7","volume":"4","author":"JR Smith","year":"2015","unstructured":"Smith JR, Roberts KD, Rybak MJ (2015) Dalbavancin: a novel lipoglycopeptide antibiotic with extended activity against Gram-positive infections. Infect Dis Ther 4(3):245\u2013258","journal-title":"Infect Dis Ther"},{"issue":"3","key":"4437_CR8","doi-asserted-by":"publisher","first-page":"e02397","DOI":"10.1128\/AAC.02397-17","volume":"62","author":"HS Sader","year":"2018","unstructured":"Sader HS, Mendes RE, Duncan LR, Pfaller MA, Flamm RK (2018) Antimicrobial activity of dalbavancin against Staphylococcus aureus with decreased susceptibility to glycopeptides, daptomycin, and\/or linezolid from U.S. Medical Centers. Antimicrob Agents Chemother 62(3):e02397","journal-title":"Antimicrob Agents Chemother"},{"key":"4437_CR9","doi-asserted-by":"publisher","first-page":"3349","DOI":"10.2147\/DDDT.S313756","volume":"15","author":"M Gatti","year":"2021","unstructured":"Gatti M, Andreoni M, Pea F, Viale P (2021) Real-world use of dalbavancin in the era of empowerment of outpatient antimicrobial treatment: a careful appraisal beyond approved indications focusing on unmet clinical needs. Drug Des Dev Ther 15:3349\u20133378","journal-title":"Drug Des Dev Ther"},{"key":"4437_CR10","unstructured":"CLSI (2018) M07ED11 Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically: eleventh edition. Clinical and Laboratory Standards Institute, Wayne"},{"key":"4437_CR11","unstructured":"CLSI (2021) M100Ed31. Performance standards for antimicrobial susceptibility testing: 31st informational supplement. Clinical and Laboratory Standards Institute, Wayne"},{"key":"4437_CR12","unstructured":"EUCAST (2021) Breakpoint tables for interpretation of MICs and zone diameters. Version 11.0, January 2021. European Committee on Antimicrobial Susceptibility Testing"},{"issue":"5","key":"4437_CR13","doi-asserted-by":"publisher","first-page":"310","DOI":"10.1136\/ejhpharm-2018-001711","volume":"27","author":"M Nunez-Nunez","year":"2020","unstructured":"Nunez-Nunez M, PharmD M, Casas-Hidalgo I, Garcia-Fumero R, Vallejo-Rodriguez I, Anguita-Santos F, Hernandez-Quero J, Cabeza-Barrera J, Ruiz-Sancho A (2020) Dalbavancin is a novel antimicrobial against Gram-positive pathogens: clinical experience beyond labelled indications. Eur J Hosp Pharm 27(5):310\u2013312","journal-title":"Eur J Hosp Pharm"},{"issue":"5","key":"4437_CR14","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1093\/cid\/ciy279","volume":"67","author":"S Tobudic","year":"2018","unstructured":"Tobudic S, Forstner C, Burgmann H, Lagler H, Ramharter M, Steininger C, Vossen MG, Winkler S, Thalhammer F (2018) Dalbavancin as primary and sequential treatment for Gram-positive infective endocarditis: 2-year experience at the General Hospital of Vienna. Clin Infect Dis 67(5):795\u2013798","journal-title":"Clin Infect Dis"},{"issue":"1","key":"4437_CR15","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1007\/s40121-021-00568-7","volume":"11","author":"PL Gonzalez","year":"2022","unstructured":"Gonzalez PL, Rappo U, Akinapelli K, McGregor JS, Puttagunta S, Dunne MW (2022) Outcomes in patients with Staphylococcus aureus bacteremia treated with dalbavancin in clinical trials. Infect Dis Ther 11(1):423\u2013434","journal-title":"Infect Dis Ther"},{"issue":"10","key":"4437_CR16","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3390\/antibiotics9100700","volume":"9","author":"L Ajaka","year":"2020","unstructured":"Ajaka L, Heil E, Schmalzle S (2020) Dalbavancin in the treatment of bacteremia and endocarditis in people with barriers to standard care. Antibiotics (Basel) 9(10):700","journal-title":"Antibiotics (Basel)"},{"issue":"5","key":"4437_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1111\/jcpt.12306","volume":"40","author":"JC Cho","year":"2015","unstructured":"Cho JC, Estrada SJ, Beltran AJ, Revuelta MP (2015) Treatment of methicillin-sensitive Staphylococcus aureus bacteremia secondary to septic phlebitis using dalbavancin. J Clin Pharm Ther 40(5):604\u2013606","journal-title":"J Clin Pharm Ther"},{"issue":"1","key":"4437_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1186\/s12941-019-0329-6","volume":"18","author":"C Hidalgo-Tenorio","year":"2019","unstructured":"Hidalgo-Tenorio C, Vinuesa D, Plata A, Martin Davila P, Iftimie S, Sequera S, Loeches B, Lopez-Cortes LE, Farinas MC, Fernandez-Roldan C, Javier-Martinez R, Munoz P, Arenas-Miras MDM, Martinez-Marcos FJ, Miro JM, Herrero C, Bereciartua E, De Jesus SE, Pasquau J (2019) DALBACEN cohort: dalbavancin as consolidation therapy in patients with endocarditis and\/or bloodstream infection produced by gram-positive cocci. Ann Clin Microbiol Antimicrob 18(1):30","journal-title":"Ann Clin Microbiol Antimicrob"},{"issue":"1","key":"4437_CR19","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1007\/s15010-020-01526-0","volume":"49","author":"F Hitzenbichler","year":"2021","unstructured":"Hitzenbichler F, Mohr A, Camboni D, Simon M, Salzberger B, Hanses F (2021) Dalbavancin as long-term suppressive therapy for patients with Gram-positive bacteremia due to an intravascular source-a series of four cases. Infection 49(1):181\u2013186","journal-title":"Infection"},{"key":"4437_CR20","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1016\/j.ijid.2018.07.016","volume":"76","author":"BM Jones","year":"2018","unstructured":"Jones BM, Keedy C, Wynn M (2018) Successful treatment of Enterococcus faecalis bacteremia with dalbavancin as an outpatient in an intravenous drug user. Int J Infect Dis 76:4\u20135","journal-title":"Int J Infect Dis"},{"issue":"8","key":"4437_CR21","doi-asserted-by":"publisher","first-page":"5007","DOI":"10.1128\/AAC.00274-15","volume":"59","author":"SP McCurdy","year":"2015","unstructured":"McCurdy SP, Jones RN, Mendes RE, Puttagunta S, Dunne MW (2015) In vitro activity of dalbavancin against drug resistant Staphylococcus aureus from a global surveillance program. Antimicrob Agents Chemother 59(8):5007\u20135009","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"4437_CR22","doi-asserted-by":"publisher","first-page":"859","DOI":"10.2165\/11534440-000000000-00000","volume":"70","author":"GG Zhanel","year":"2010","unstructured":"Zhanel GG, Calic D, Schweizer F, Zelenitsky S, Adam H, Lagace-Wiens PR, Rubinstein E, Gin AS, Hoban DJ, Karlowsky JA (2010) New lipoglycopeptides: a comparative review of dalbavancin, oritavancin and telavancin. Drugs 70(7):859\u2013886","journal-title":"Drugs"}],"container-title":["European Journal of Clinical Microbiology &amp; Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10096-022-04437-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10096-022-04437-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,4,22]],"date-time":"2022-04-22T11:08:46Z","timestamp":1650625726000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10096-022-04437-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,3,30]]},"references-count":22,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,5]]}},"alternative-id":["4437"],"URL":"https:\/\/doi.org\/10.1007\/s10096-022-04437-0","relation":{},"ISSN":["0934-9723","1435-4373"],"issn-type":[{"value":"0934-9723","type":"print"},{"value":"1435-4373","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,3,30]]},"assertion":[{"value":"17 January 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 March 2022","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 March 2022","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}},{"value":"The content has been read and approved by all co-authors and the manuscript has not been submitted elsewhere. Furthermore, all authors agree to transfer the copyright, following the policies of the journal at the time of acceptance\/publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"JMI Laboratories has no conflicts of interest to declare.JMI Laboratories contracted to perform services in 2018\u20132020 for Achaogen, Inc., Affinity Biosensors, Albany College of Pharmacy and Health Sciences, Allecra Therapeutics, Allergan, Amicrobe Advanced Biomaterials, Inc., American Proficiency Institute, AmpliPhi Biosciences Corp., Amplyx Pharma, Antabio, Arietis Corp., Arixa Pharmaceuticals, Inc., Artugen Therapeutics USA, Inc., Astellas Pharma Inc., Athelas, Becton, Basilea Pharmaceutica Ltd., Bayer AG, Becton, Beth Israel Deaconess Medical Center, BIDMC, bioMerieux, Inc., bioMerieux SA, BioVersys Ag, Boston Pharmaceuticals, Bugworks Research Inc., CEM-102 Pharmaceuticals, Cepheid, Cidara Therapeutics, Inc., Cipla, Contrafect, Cormedix Inc., Crestone, Inc., Curza, CXC7, DePuy Synthes, Destiny Pharma, Dickinson and Company, Discuva Ltd., Dr. Falk Pharma GmbH, Emery Pharma, Entasis Therapeutics, Eurofarma Laboratorios SA, Fedora Pharmaceutical, F. Hoffmann-La Roche Ltd., Fimbrion Therapeutics, US Food and Drug Administration, Fox Chase Chemical Diversity Center, Inc., Gateway Pharmaceutical LLC, GenePOC Inc., Geom Therapeutics, Inc., GlaxoSmithKline plc, Guardian Therapeutics, Hardy Diagnostics, Harvard University, Helperby, HiMedia Laboratories, ICON plc, Idorsia Pharmaceuticals Ltd., IHMA, Iterum Therapeutics plc, Janssen Research & Development, Johnson & Johnson, Kaleido Biosciences, KBP Biosciences, Laboratory Specialists, Inc., Luminex, Matrivax, Mayo Clinic, Medpace, Meiji Seika Pharma Co., Ltd., Melinta Therapeutics, Inc., Menarini, Merck & Co., Inc., Meridian Bioscience Inc., Micromyx, Microchem Laboratory, MicuRx Pharmaceutics, Inc., Mutabilis Co., N8 Medical, Nabriva Therapeutics plc, National Institutes of Health, NAEJA-RGM, National University of Singapore, North Bristol NHS Trust, Novartis AG, Novome Biotechnologies, Oxoid Ltd., Paratek Pharmaceuticals, Inc., Pfizer, Inc., Pharmaceutical Product Development, LLC, Polyphor Ltd., Prokaryotics Inc., QPEX Biopharma, Inc., Ra Pharmaceuticals, Inc., Rhode Island Hospital, RIHML, Roche, Roivant Sciences, Ltd., Safeguard Biosystems, Salvat, Scynexis, Inc., SeLux Diagnostics, Inc., Shionogi and Co., Ltd., SinSa Labs, Specific Diagnostics, Spero Therapeutics, Summit Pharmaceuticals International Corp., SuperTrans Medical LT, Synlogic, T2 Biosystems, Taisho Pharmaceutical Co., Ltd., TenNor Therapeutics Ltd., Tetraphase Pharmaceuticals, The Medicines Company, The University of Queensland, Theravance Biopharma, Thermo Fisher Scientific, Tufts Medical Center, Universite de Sherbrooke, University of Colorado, University of Southern California-San Diego, University of Iowa, University of Iowa Hospitals and Clinics, University of North Texas Health Science Center, University of Wisconsin, UNT System College of Pharmacy, URMC, UT Southwestern, VenatoRx, Viosera Therapeutics, Vyome Therapeutics Inc., Wayne State University, Wockhardt, Yukon Pharmaceuticals, Inc., Zai Lab, and Zavante Therapeutics, Inc. There are no speakers\u2019 bureaus or stock options to declare.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}